Absolutely. The connection between Depo-Provera and meningioma—a type of brain tumor—is supported by some of the strongest scientific evidence we’ve seen in pharmaceutical litigation. According to a peer-reviewed study published in The BMJ, women who used this birth control injection for over a year had a 5.6 times higher risk of developing meningioma compared to non-users.

This is a significant risk multiplier. In the legal world, numbers like this don’t just raise eyebrows—they turn heads. Such strong statistical evidence lays the foundation for high-stakes litigation and strengthens the position of plaintiffs seeking justice.

While there was a brief slowdown earlier in 2025, the legal momentum behind these cases is growing rapidly again. With a federal multidistrict litigation (MDL) now underway and assigned to an experienced judge, many expect this litigation to accelerate. Among mass tort attorneys, Depo-Provera is currently one of the most active and closely watched dockets in the country.